Mindfulness and Sex Education for Sexual Dysfunction in Breast Cancer Survivors: Mediators and Moderators of Treatment Outcome.

J Sex ResSep 3, 2025 (epub)

Lori A Brotto, Bozena Zdaniuk, Piper Slonecker et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined mechanisms and moderators of outcomes after 8-week mindfulness-based cognitive therapy (MBCT) or supportive-expressive sex education therapy (STEP) for sexual dysfunction in 116 breast cancer survivors (mean age 49.9 ± 9.5 years). Participants completed assessments before treatment, immediately afterward, and 6 months later. Increased pain acceptance mediated improvements in sexual desire and reductions in sexual distress and vaginal pain; reduced pain catastrophizing mediated lower sexual distress. Treatment expectations and baseline anxiety, depression, and age were among factors associated with differences in outcomes.

Key findings

  • Increased pain acceptance mediated improved sexual desire and reduced sexual distress and vaginal pain.
  • Reduced pain catastrophizing mediated improvement in sexual distress.
  • Higher treatment expectations were associated with greater reductions in sexual distress; low baseline anxiety was associated with greater improvements in desire and distress.
  • Low baseline depression predicted greater improvement in desire only in STEP; older STEP participants improved more than younger participants.

Why it matters

The findings suggest that pain-related beliefs and acceptance may be relevant targets when addressing sexual dysfunction after breast cancer. They also indicate that outcomes can vary with patient characteristics and expectations, and that these relationships may differ between treatment approaches. Understanding such factors may help clinicians interpret treatment response and inform further evaluation of tailored support.

What to keep in mind

The abstract reports mediator and moderator analyses within a trial but does not provide effect sizes or details on the magnitude of these associations.

Source

Published in J Sex Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.